Abstract
Introduction: The immunopathogenesis of multiple sclerosis (MS) is a main field of research, together with the mechanism of action of most immune therapies in this disease, such as interferon beta. Interleukin (IL)-17 is considered to play a central part in the initial immune cascade in MS, though there are numerous interactions between other cytokines that might explain the heterogeneity of disease evolution and treatment response.
Material and Methods: We tested the serum levels of IL-17A, IL-10 and transforming growth factor (TGF-β) using the enzyme-linked immunosorbent assay method in three small groups of relapsing-remitting MS patients: 10 being naïve without treatment, 10 patients receiving Avonex treatment early in the MS evolution (≤ one year from the MS onset) and 12 MS patients who received Avonex later in the disease evolution. The values were compared with those obtained from 32 healthy subjects using statistical analysis.
Results: In the naive multiple sclerosis group: IL-17A values were statistically higher than among healthy subjects; IL- 17A inversely correlated with MS duration; serum IL-17A negatively correlated with TGF-β. A direct correlation was found between the serum titre of IL-17A and IL-10 in the early treated multiple sclerosis group; the titre of IL-17A was significantly reduced compared with that from the late treated multiple sclerosis group.
Conclusion: The role in MS pathology of IL-17A, IL-10 and TGF-β is only partially elucidated. IL-17 plays an important role in the inflammatory phase of relapsing-remitting MS and is diminished by Avonex mainly if this disease modifying treatment is administered early in the evolution of MS.
Keywords: Immunopathology, interleukin-17, interleukin-10, multiple sclerosis, transforming growth factor-β.
CNS & Neurological Disorders - Drug Targets
Title:An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β
Volume: 14 Issue: 6
Author(s): Rodica Balasa, Smaranda Maier, Septimiu Voidazan, Adina Hutanu, Zoltan Bajko and Anca Motataianu
Affiliation:
Keywords: Immunopathology, interleukin-17, interleukin-10, multiple sclerosis, transforming growth factor-β.
Abstract: Introduction: The immunopathogenesis of multiple sclerosis (MS) is a main field of research, together with the mechanism of action of most immune therapies in this disease, such as interferon beta. Interleukin (IL)-17 is considered to play a central part in the initial immune cascade in MS, though there are numerous interactions between other cytokines that might explain the heterogeneity of disease evolution and treatment response.
Material and Methods: We tested the serum levels of IL-17A, IL-10 and transforming growth factor (TGF-β) using the enzyme-linked immunosorbent assay method in three small groups of relapsing-remitting MS patients: 10 being naïve without treatment, 10 patients receiving Avonex treatment early in the MS evolution (≤ one year from the MS onset) and 12 MS patients who received Avonex later in the disease evolution. The values were compared with those obtained from 32 healthy subjects using statistical analysis.
Results: In the naive multiple sclerosis group: IL-17A values were statistically higher than among healthy subjects; IL- 17A inversely correlated with MS duration; serum IL-17A negatively correlated with TGF-β. A direct correlation was found between the serum titre of IL-17A and IL-10 in the early treated multiple sclerosis group; the titre of IL-17A was significantly reduced compared with that from the late treated multiple sclerosis group.
Conclusion: The role in MS pathology of IL-17A, IL-10 and TGF-β is only partially elucidated. IL-17 plays an important role in the inflammatory phase of relapsing-remitting MS and is diminished by Avonex mainly if this disease modifying treatment is administered early in the evolution of MS.
Export Options
About this article
Cite this article as:
Balasa Rodica, Maier Smaranda, Voidazan Septimiu, Hutanu Adina, Bajko Zoltan and Motataianu Anca, An Intricate Mechanism of Action of Avonex in Relapsing Remitting Multiple Sclerosis Patients: Variation of Serum Titre of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-β, CNS & Neurological Disorders - Drug Targets 2015; 14 (6) . https://dx.doi.org/10.2174/1871527314666150317225441
DOI https://dx.doi.org/10.2174/1871527314666150317225441 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to
Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology Proinflammatory Cytokines and Sickness Behavior in Rheumatic Diseases
Current Pharmaceutical Design ADAMTS Proteinases: Potential Therapeutic Targets?
Current Pharmaceutical Biotechnology Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Potential Application of Biliverdin Reductase and its Fragments to Modulate insulin/IGF-1/MAPK/PI3-K Signaling Pathways in Therapeutic Settings
Current Drug Targets MiR-19b Functions as a Potential Protector in Experimental Autoimmune Encephalomyelitis
Current Molecular Medicine Pharmacological Perspectives of Wasp Venom
Protein & Peptide Letters Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity
Current Drug Targets Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry The Interplay between the Gut Immune System and Microbiota in Health and Disease: Nutraceutical Intervention for Restoring Intestinal Homeostasis
Current Pharmaceutical Design Oxidative Stress Protection by Novel Telomerase Activators in Mesenchymal Stem Cells Derived from Healthy and Diseased Individuals
Current Molecular Medicine Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection
Infectious Disorders - Drug Targets Targeting the Coagulation Factor Fibrinogen for Arthritis Therapy
Current Pharmaceutical Biotechnology Experimental Strategies in Autoimmunity: Antagonists of Cytokines and their Receptors, Nanocarriers, Inhibitors of Immunoproteasome, Leukocyte Migration and Protein Kinases
Current Pharmaceutical Design Impact of MCP -1 in Atherosclerosis
Current Pharmaceutical Design Histamine H4 Receptors and their Significance
Current Immunology Reviews (Discontinued) Immune Regulation by the Posttranslational Modification O-GlcNAc
Current Signal Transduction Therapy Combined Therapies for Lysosomal Storage Diseases
Current Molecular Medicine Nanotech Revolution for the Anti-Cancer Drug Delivery through Blood- Brain-Barrier
Current Cancer Drug Targets